CN106511363A - Western medicine composition for treating bronchitis and preparation method of western medicine composition - Google Patents
Western medicine composition for treating bronchitis and preparation method of western medicine composition Download PDFInfo
- Publication number
- CN106511363A CN106511363A CN201611116089.3A CN201611116089A CN106511363A CN 106511363 A CN106511363 A CN 106511363A CN 201611116089 A CN201611116089 A CN 201611116089A CN 106511363 A CN106511363 A CN 106511363A
- Authority
- CN
- China
- Prior art keywords
- parts
- powder
- aminoacid
- western medicine
- morroniside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010006451 bronchitis Diseases 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- YTZSBJLNMIQROD-SFBCHFHNSA-N Morroniside Chemical compound O([C@@H]1OC=C([C@H]2C[C@H](O)O[C@@H](C)[C@H]21)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YTZSBJLNMIQROD-SFBCHFHNSA-N 0.000 claims abstract description 50
- 150000001413 amino acids Chemical class 0.000 claims abstract description 45
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 39
- YTZSBJLNMIQROD-UHFFFAOYSA-N (4aS)-1c-beta-D-glucopyranosyloxy-6xi-hydroxy-8t-methyl-(4ar,8ac)-5,6,8,8a-tetrahydro-1H,4aH-pyrano[3,4-c]pyran-4-carboxylic acid methyl ester Natural products C12C(C)OC(O)CC2C(C(=O)OC)=COC1OC1OC(CO)C(O)C(O)C1O YTZSBJLNMIQROD-UHFFFAOYSA-N 0.000 claims abstract description 25
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 25
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960003556 aminophylline Drugs 0.000 claims abstract description 25
- 229960004436 budesonide Drugs 0.000 claims abstract description 25
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960000282 metronidazole Drugs 0.000 claims abstract description 25
- 229960003291 chlorphenamine Drugs 0.000 claims abstract description 15
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 13
- 229930195725 Mannitol Natural products 0.000 claims abstract description 13
- 239000000594 mannitol Substances 0.000 claims abstract description 13
- 235000010355 mannitol Nutrition 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 239000000843 powder Substances 0.000 claims description 70
- 235000001014 amino acid Nutrition 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 17
- 229930003944 flavone Natural products 0.000 claims description 17
- 235000011949 flavones Nutrition 0.000 claims description 17
- 150000002213 flavones Chemical class 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 13
- 239000011259 mixed solution Substances 0.000 claims description 12
- 229930014669 anthocyanidin Natural products 0.000 claims description 11
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 11
- 235000008758 anthocyanidins Nutrition 0.000 claims description 11
- 150000007946 flavonol Chemical class 0.000 claims description 8
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 claims description 8
- 235000011957 flavonols Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 4
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 4
- 235000005513 chalcones Nutrition 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 235000018977 lysine Nutrition 0.000 claims description 4
- 229960002510 mandelic acid Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 229940013618 stevioside Drugs 0.000 claims description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- -1 bisflavone Chemical compound 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 3
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 3
- 235000008696 isoflavones Nutrition 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 2
- 239000004744 fabric Substances 0.000 claims description 2
- 150000002212 flavone derivatives Chemical class 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims 1
- 241000207199 Citrus Species 0.000 claims 1
- 235000020971 citrus fruits Nutrition 0.000 claims 1
- 239000000686 essence Substances 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 abstract description 7
- 208000007451 chronic bronchitis Diseases 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 abstract 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 abstract 2
- 229930002877 anthocyanin Natural products 0.000 abstract 1
- 235000010208 anthocyanin Nutrition 0.000 abstract 1
- 239000004410 anthocyanin Substances 0.000 abstract 1
- 150000004636 anthocyanins Chemical class 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 abstract 1
- 150000002215 flavonoids Chemical class 0.000 abstract 1
- 235000017173 flavonoids Nutrition 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 235000004400 serine Nutrition 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DXWBUGAELMRQAZ-UHFFFAOYSA-N (Z)-but-2-enedioic acid chlorobenzene Chemical compound ClC1=CC=CC=C1.C(C=C/C(=O)O)(=O)O DXWBUGAELMRQAZ-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses western medicine composition for treating bronchitis. The western medicine composition is prepared from the following raw materials in parts by weight: 4-8 parts of auxiliary materials, 0.5-4 parts of amino acid, 3-8 parts of total flavonoid, 1-4 parts of mannitol, 5-10 parts of chlorpheniramine, 4-12 parts of metronidazole, 0.5-3 parts of aminophylline, 0.1-1.5 parts of anthocyanin, 8-15 parts of morroniside, 0.1-0.5 parts of chlorpheniramine maleate, 0.5-2 parts of oryzanol, 2-6 parts of budesonide, 2-6 parts of amino acid and 18-32 parts of an ethanol solution. The invention also discloses a preparation method of the western medicine composition. The preparation method adopts widely sourced raw materials, is simple in preparation process, low in investment cost of production equipment and suitable for large-scale industrial production; components such as chlorpheniramine, chlorpheniramine maleate, budesonide and the like play a synergistic role, so that the composition can fundamentally cure chronic bronchitis, has a curative effect superior to that of existing products, has no toxic or side effects and has broad market prospect.
Description
Technical field
The present invention relates to field of medicine preparation, specifically a kind of Western medicine combination for treating bronchitis.
Background technology
With the increase of life stress and increasing for various bad life habits, people face the threat of various diseases,
Tracheitiies are exactly one of which.Bronchitis refer to the chronic nonspecific inflammation of trachea-bronchial epithelial cell mucosa and its surrounding tissue.
Bronchitis main cause is that the repeated infection of virus and antibacterial defines bronchial chronic nonspecific inflammation.When under temperature
Drop, the decline of respiratory tract small blood vessel spasm ischemia, defense function etc. are beneficial to pathogenic；The chronic stimulations such as smog dust, atmosphere pollution
Can fall ill；Smoking makes bronchospasm, mucosa variation, ciliary movement is reduced, mucilage secretion increases advantageous infectivity；Intolerance factors
There is certain relation.Bronchitis are divided into acute bronchitiss and chronic bronchitiss, and chronic bronchitiss are most common of which,
The patient for suffering with chronic bronchitis all be using Western medicine combined therapy, but the combination of existing Western medicine can only be alleviated or temporarily
Play a part of inflammation-diminishing and cough-controlling, it is impossible to fundamentally cure chronic bronchitiss, this just brings inconvenience for patient.
The content of the invention
It is an object of the invention to provide a kind of Western medicine combination for treating bronchitis, to solve to carry in above-mentioned background technology
The problem for going out.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine combination for treating bronchitis, is made up of according to weight portion following raw material：Adjuvant 4-8 parts, aminoacid
0.5-4 parts, total flavones 3-8 parts, Mannitol 1-4 part, chlorphenamine 5-10 parts, metronidazole 4-12 parts, aminophylline 0.5-3 parts, cyanine
Plain 0.1-1.5 parts, morroniside 8-15 parts, Chlorphenamine Maleate 0.1-0.5 part, oryzanol 0.5-2 parts, budesonide 2-6 parts,
Aminoacid 2-6 parts and ethanol solution 18-32 parts.
As further scheme of the invention：Total flavones adopt flavonol, bisflavone, isoflavone, flavonol and chalcone
One or more mixture, aminoacid using Herba Marsileae Quadrifoliae aminoacid, citric acid, Caulis Sacchari sinensis acid and mandelic acid one or more
Mixture, aminoacid using glutamic acid, lysine, aspartic acid and serine one or more mixture.
As further scheme of the invention：Adjuvant adopts dextrin, Lactose, starch, methylcellulose, carboxymethyl cellulose
With the mixture of one or more of stevioside, the weight fraction of ethanol solution is 45-65%.
The preparation method of the Western medicine combination of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 100- is crossed
120 mesh sieve, obtain metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder inhalation
End, it is standby；
Step 2, by aminoacid, total flavones, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate
During quick powder and budesonide powder add ethanol solution and at normal temperatures blender is with the rotating speed stirring 15- of 60-120rpm
30 minutes, obtain the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Mix side and add aminoacid, be added completely into after aminoacid finishes, blender is stirred with the rotating speed of 150-360rpm under 35-48 degree Celsius
When mixing 45-90 minutes, then carrying out being evaporated to 65 DEG C, relative density is 1.20-1.30, obtains concentrated solution, then carries out spray dried
Dry to obtain dry extract, addition adjuvant makes powder, capsule, tablet or granule.
Compared with prior art, the invention has the beneficial effects as follows：Extensively, preparation process is simple is raw for raw material sources of the present invention
Produce equipment investment cost low, it is adaptable to large-scale industrial production；Chlorphenamine, Chlorphenamine Maleate, cloth ground in the present invention
The components such as Nai De play synergism, can fundamentally cure chronic bronchitiss, and therapeutic effect far superior to existing product is simultaneously
And no toxic and side effects, wide market.
Specific embodiment
The technical scheme of this patent is described in more detail with reference to specific embodiment.
Embodiment 1
A kind of Western medicine combination for treating bronchitis, is made up of according to weight portion following raw material：4 parts of adjuvant, aminoacid 0.5
Part, 3 parts of total flavones, 1 part of Mannitol, 5 parts of chlorphenamine, 4 parts of metronidazole, 0.5 part of aminophylline, 0.1 part of anthocyanidin, 8 parts of morroniside,
18 parts of 0.1 part of Chlorphenamine Maleate, 0.5 part of oryzanol, 2 parts of budesonide, 2 parts of aminoacid and ethanol solution.Total flavones are adopted
With the mixture of flavonol, bisflavone and chalcone, aminoacid adopts Herba Marsileae Quadrifoliae aminoacid, and aminoacid adopts glutamic acid and lysine
Mixture.
The preparation method of the Western medicine combination of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 100 mesh are crossed
Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder, standby
With；
Step 2, by Herba Marsileae Quadrifoliae aminoacid, total flavones, metronidazole powder, aminophylline powder, morroniside powder, maleic acid chlorobenzene
During that quick powder and budesonide powder add ethanol solution and at normal temperatures blender stirs 15 points with the rotating speed of 60rpm
Clock, obtains the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Mix side and add aminoacid, be added completely into after aminoacid finishes, blender stirs 60 points with the rotating speed of 240rpm under 35 degrees Celsius
Clock, then when carrying out being evaporated to 65 DEG C, relative density is 1.22, obtains concentrated solution, then carry out spray drying obtaining dry extract
Powder, addition adjuvant make powder, capsule, tablet or granule.
Embodiment 2
A kind of Western medicine combination for treating bronchitis, is made up of according to weight portion following raw material：6 parts of adjuvant, amino acid/11 .5
Part, 5 parts of total flavones, 2 parts of Mannitol, 7 parts of chlorphenamine, 6 parts of metronidazole, 1.5 parts of aminophylline, 0.7 part of anthocyanidin, morroniside 11
Part, 0.3 part of Chlorphenamine Maleate, 1 part of oryzanol, 3.5 parts of budesonide, 4 parts of aminoacid and 22 parts of ethanol solution.Adjuvant is adopted
With dextrin, the mixture of newborn sugar and starch, the weight fraction of ethanol solution is 54%.
The preparation method of the Western medicine combination of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 110 mesh are crossed
Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder, standby
With；
Step 2, by aminoacid, total flavones, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate
During quick powder and budesonide powder add ethanol solution and at normal temperatures blender is stirred 20 minutes with the rotating speed of 90rpm,
Obtain the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Mix side and add aminoacid, be added completely into after aminoacid finishes, blender stirs 60 points with the rotating speed of 210rpm under 39 degrees Celsius
Clock, then when carrying out being evaporated to 65 DEG C, relative density is 1.24, obtains concentrated solution, then carry out spray drying obtaining dry extract
Powder, addition adjuvant make powder, capsule, tablet or granule.
Embodiment 3
A kind of Western medicine combination for treating bronchitis, is made up of according to weight portion following raw material：7 parts of adjuvant, aminoacid 3.5
Part, 6.5 parts of total flavones, 3 parts of Mannitol, 9 parts of chlorphenamine, 11 parts of metronidazole, 2.5 parts of aminophylline, 1.2 parts of anthocyanidin, morroniside
28 parts of 13 parts, 0.4 part of Chlorphenamine Maleate, 1.6 parts of oryzanol, 5.4 parts of budesonide, 5 parts of aminoacid and ethanol solution.Always
Flavone adopts flavonol, aminoacid to adopt serine using Caulis Sacchari sinensis acid and the mixture of mandelic acid, aminoacid.Adjuvant adopts carboxylic first
The mixture of base cellulose and stevioside, the weight fraction of ethanol solution is 60%.
The preparation method of the Western medicine combination of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 120 mesh are crossed
Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder, standby
With；
Step 2, by aminoacid, flavonol, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate
During quick powder and budesonide powder add ethanol solution and at normal temperatures blender is stirred 24 minutes with the rotating speed of 100rpm,
Obtain the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Mix side and add serine, be added completely into after aminoacid finishes, blender stirs 75 points with the rotating speed of 300rpm under 42 degrees Celsius
Clock, then when carrying out being evaporated to 65 DEG C, relative density is 1.28, obtains concentrated solution, then carry out spray drying obtaining dry extract
Powder, addition adjuvant make powder, capsule, tablet or granule.
Embodiment 4
A kind of Western medicine combination for treating bronchitis, is made up of according to weight portion following raw material：8 parts of adjuvant, aminoacid 4
Part, 8 parts of total flavones, 4 parts of Mannitol, 10 parts of chlorphenamine, 12 parts of metronidazole, 3 parts of aminophylline, 1.5 parts of anthocyanidin, morroniside 15
Part, 0.5 part of Chlorphenamine Maleate, 2 parts of oryzanol, 6 parts of budesonide, 6 parts of aminoacid and 32 parts of ethanol solution.Total flavones are adopted
With the mixture of flavonol, bisflavone, isoflavone, flavonol and chalcone, aminoacid is using Herba Marsileae Quadrifoliae aminoacid, citric acid, Caulis Sacchari sinensis
Acid and the mixture of mandelic acid, mixture of the aminoacid using glutamic acid, lysine, aspartic acid and serine.Adjuvant is adopted
The mixture of dextrin, Lactose, starch, methylcellulose, carboxymethyl cellulose and stevioside, the weight fraction of ethanol solution is
65%.
The preparation method of the Western medicine combination of the treatment bronchitis, comprises the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 110 mesh are crossed
Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder, standby
With；
Step 2, by aminoacid, total flavones, metronidazole powder, aminophylline powder, morroniside powder, chlorphenamine maleate
During quick powder and budesonide powder add ethanol solution and at normal temperatures blender is stirred 20 minutes with the rotating speed of 120rpm,
Obtain the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Mix side and add aminoacid, be added completely into after aminoacid finishes, blender stirs 60 points with the rotating speed of 360rpm under 48 degrees Celsius
Clock, then when carrying out being evaporated to 65 DEG C, relative density is 1.25, obtains concentrated solution, then carry out spray drying obtaining dry extract
Powder, addition adjuvant make powder, capsule, tablet or granule.
500 patients, men and women are selected respectively to account for half.By 500 patient's stochastic averaginas be divided into 5 groups and per group in sex and
It is almost identical on age.Patient of the product of embodiment 1-4 to 1-4 groups is taken, existing product is taken to 5 groups of patients, often
It three times, each 4g and warm water delivery service is adopted, continue two weeks, therapeutic effect is shown in Table 1.Treatment standard：Cure：Thoroughly eradicate
Chronic bronchitiss, clinical symptom disappearance no longer recur in two years；Effectively：Clinical symptoms are obviously improved；It is invalid：Clinical symptoms
Substantially do not change, or even increase.
Table 1
As it can be seen from table 1 the cure rate of the product of embodiment 1-4 is more than 75%, significantly larger than existing product
47%；The effective percentage of the product of embodiment 1-4 more than 98%, significantly larger than the 73% of existing product, the product of embodiment 1-4
During patient's use, there is not any discomfort in patient.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of description is only that those skilled in the art should for clarity
Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (4)
1. a kind of Western medicine combination for treating bronchitis, it is characterised in that be made up of according to weight portion following raw material：Adjuvant 4-8
Part, aminoacid 0.5-4 parts, total flavones 3-8 parts, Mannitol 1-4 part, chlorphenamine 5-10 parts, metronidazole 4-12 parts, aminophylline 0.5-
3 parts, anthocyanidin 0.1-1.5 parts, morroniside 8-15 parts, Chlorphenamine Maleate 0.1-0.5 part, oryzanol 0.5-2 parts, cloth ground how
Moral 2-6 part, aminoacid 2-6 parts and ethanol solution 18-32 parts.
2. the Western medicine combination for the treatment of bronchitis according to claim 1, it is characterised in that the total flavones adopt flavone
One or more mixture of alcohol, bisflavone, isoflavone, flavonol and chalcone, aminoacid adopt Herba Marsileae Quadrifoliae aminoacid, Citrus
One or more mixture of acid, Caulis Sacchari sinensis acid and mandelic acid, aminoacid adopt glutamic acid, lysine, aspartic acid and silk
One or more mixture of propylhomoserin.
3. the Western medicine combination for the treatment of bronchitis according to claim 1 and 2, it is characterised in that the adjuvant is using paste
The mixture of one or more of essence, Lactose, starch, methylcellulose, carboxymethyl cellulose and stevioside, the weight of ethanol solution
Amount fraction is 45-65%.
4. the preparation method that a kind of Western medicine of the treatment bronchitis as described in claim 1-3 is arbitrary is combined, it is characterised in that
Comprise the following steps that：
Step one, metronidazole, aminophylline, morroniside, Chlorphenamine Maleate and budesonide are crushed and 100-120 mesh is crossed
Sieve, obtains metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder and budesonide powder, standby
With；
Step 2, by aminoacid, total flavones, metronidazole powder, aminophylline powder, morroniside powder, Chlorphenamine Maleate powder
During end and budesonide powder add ethanol solution and at normal temperatures blender is with 15-30 point of the rotating speed of 60-120rpm stirring
Clock, obtains the first mixed solution；
Mannitol, chlorphenamine, anthocyanidin and oryzanol are added in the first mixed solution and are stirred, while stirring by step 3
Aminoacid is added, is added completely into after aminoacid finishes, blender is stirred with the rotating speed of 150-360rpm under 35-48 degree Celsius
45-90 minutes, then when carrying out being evaporated to 65 DEG C, relative density is 1.20-1.30, obtains concentrated solution, then carries out spray dried
Dry to obtain dry extract, addition adjuvant makes powder, capsule, tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611116089.3A CN106511363A (en) | 2016-12-07 | 2016-12-07 | Western medicine composition for treating bronchitis and preparation method of western medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611116089.3A CN106511363A (en) | 2016-12-07 | 2016-12-07 | Western medicine composition for treating bronchitis and preparation method of western medicine composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511363A true CN106511363A (en) | 2017-03-22 |
Family
ID=58341602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611116089.3A Withdrawn CN106511363A (en) | 2016-12-07 | 2016-12-07 | Western medicine composition for treating bronchitis and preparation method of western medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511363A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762493A (en) * | 2004-10-19 | 2006-04-26 | 上海中西制药有限公司 | Process for preparing compound aminophylline tablet |
| CN103989695A (en) * | 2014-06-06 | 2014-08-20 | 杨献华 | Pharmaceutical composition for treating bronchial asthma and application thereof |
-
2016
- 2016-12-07 CN CN201611116089.3A patent/CN106511363A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1762493A (en) * | 2004-10-19 | 2006-04-26 | 上海中西制药有限公司 | Process for preparing compound aminophylline tablet |
| CN103989695A (en) * | 2014-06-06 | 2014-08-20 | 杨献华 | Pharmaceutical composition for treating bronchial asthma and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104824346A (en) | Compound pig feed and preparation method thereof | |
| CN104435216A (en) | Ephedra and apricot cough relieving traditional Chinese medicine dispersible tablet and preparation method thereof | |
| CN103704514B (en) | Feed being used for the treatment of porcine contagious pleuropneumonia and preparation method thereof | |
| CN102847101A (en) | Ephedra-cassia twig cold-dispelling capsule | |
| CN106511363A (en) | Western medicine composition for treating bronchitis and preparation method of western medicine composition | |
| CN105412604A (en) | Traditional Chinese medicine composition for auxiliary treatment of diabetes and preparation method of traditional Chinese medicine composition | |
| CN116139257A (en) | Traditional Chinese medicine formula for treating postpartum hypogalactia of sow and preparation method thereof | |
| CN104547056A (en) | Externally used navel patch for treating infantile diarrhea and preparation method thereof | |
| CN106692170A (en) | Medicine for treating bronchitis and preparing method thereof | |
| CN102670863B (en) | Compound propolis composition for treating acariasis of domestic animal and preparation method thereof | |
| CN106727641A (en) | It is a kind of to treat medicine of bronchitis and preparation method thereof | |
| CN111557917A (en) | Preparation method of radix puerariae decoction particles | |
| CN104367726A (en) | Blood sugar-reducing and qi and blood-replenishing sleep regulating tea and production method thereof | |
| CN104069176B (en) | Stick scattered and preparation method thereof in a kind of oral cavity | |
| CN107669899A (en) | A kind of Chinese patent drug for treating chronic gastritis and preparation method thereof | |
| CN106581628A (en) | Traditional Chinese medicine composition for treating asthma and trachitis and preparation method thereof | |
| CN105106296A (en) | Traditional Chinese medicine styptic powder for treating haemorrhoid hemorrhage syndrome | |
| CN106031488A (en) | Sanchi flower soup stock for clearing heat and generating body fluid and preparation method thereof | |
| CN104784566A (en) | Traditional Chinese medicine for treating respiratory tract infection of children | |
| CN105707335A (en) | Radix asparagi yin nourishing and dryness moistening tea substitute brewing potion and preparation method thereof | |
| CN106729110A (en) | A kind of quick-acting disperse accumulations balls and preparation method thereof | |
| CN103638467A (en) | Medicine for treating gynecomastia and preparation method of medicine | |
| CN113546151A (en) | Traditional Chinese medicine granule for treating esophageal cancer and preparation method thereof | |
| CN103933136A (en) | Traditional Chinese medicinal preparation for treating hemorrhoid diseases and preparation method thereof | |
| CN107468934A (en) | A kind of capsule medicine for treating chronic bronchitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170322 |
|
| WW01 | Invention patent application withdrawn after publication |